197 related articles for article (PubMed ID: 34831012)
1. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic effects of RAC1 and tumor-related RAC1b on NIS expression in thyroid.
Faria M; Félix D; Domingues R; Bugalho MJ; Matos P; Silva AL
J Mol Endocrinol; 2019 Nov; 63(4):309-320. PubMed ID: 31590142
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
4. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
Zhang H; Chen D
Thyroid Res; 2018; 11():13. PubMed ID: 30337961
[TBL] [Abstract][Full Text] [Related]
5. TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells.
Faria M; Domingues R; Paixão F; Bugalho MJ; Matos P; Silva AL
PLoS One; 2020; 15(2):e0228794. PubMed ID: 32049985
[TBL] [Abstract][Full Text] [Related]
6. Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer.
Faria M; Domingues R; Bugalho MJ; Silva AL; Matos P
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771624
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
9. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
10. Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells.
Faria M; Vareda J; Miranda M; Bugalho MJ; Silva AL; Matos P
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358781
[TBL] [Abstract][Full Text] [Related]
11. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
Ingeson-Carlsson C; Nilsson M
Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
[TBL] [Abstract][Full Text] [Related]
13. Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells.
Kogai T; Liu YY; Mody K; Shamsian DV; Brent GA
J Biol Chem; 2012 Jan; 287(5):3292-300. PubMed ID: 22157753
[TBL] [Abstract][Full Text] [Related]
14. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
Luckett KA; Cracchiolo JR; Krishnamoorthy GP; Leandro-Garcia LJ; Nagarajah J; Saqcena M; Lester R; Im SY; Zhao Z; Lowe SW; de Stanchina E; Sherman EJ; Ho AL; Leach SD; Knauf JA; Fagin JA
Endocr Relat Cancer; 2021 May; 28(6):391-402. PubMed ID: 33890869
[TBL] [Abstract][Full Text] [Related]
17. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
18. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
19. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
[TBL] [Abstract][Full Text] [Related]
20. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
